New study aims to predict early death risk in elderly kidney patients
NCT ID NCT02910908
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows people over 75 with advanced chronic kidney disease to better understand their health and treatment paths. Researchers want to create a tool that predicts which patients are at high risk of dying soon after starting dialysis. The goal is to help patients, families, and doctors make more informed decisions about treatment options like dialysis, transplant, or conservative care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could give doctors a simple way to predict which elderly kidney patients are at highest risk of dying soon, helping families and doctors make better care decisions.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve health. The prediction tool may not be accurate enough to change outcomes in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nîmes
Nîmes, Gard, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- A regenerative graft could rethink dialysis access
- Pumpkin seed oil may fight inflammation in kidney patients — a trial puts it to the test